argenx, a known player in the bio-tech market, recently announced a series of major findings. The company's annual general meeting resulted in several decisions, including some shareholders blocking a new payment policy, despite high attendance. According to Wedbush, argenx secured a spot on their 'Best Ideas List' and was also highlighted for its strategic priorities set out for 2025. The FDA recently approved the syringe version of argenx's immune disorder drug, and the company CEO, Tim Van Hauwermeiren, is set to discuss latest immunology breakthroughs at the BofA Healthcare Conference. Furthermore, promising results from the company's ALKIVIA study indicated a 'Buy' rating. argenx builds on the strength of its drug, Vyvgart, obtaining FDA approval for a prefilled syringe and announcing sales momentum of the drug. The FDA has also approved argenx’s VYVGART Hytrulo pre-filled syringe for self-injection. argenx reportedly experienced record growth and strategic advances during its Q1 2025 Earnings Call and is set to expand its pipeline due to Vyvgart's momentum.
argenx News Analytics from Thu, 19 Sep 2024 07:00:00 GMT to Thu, 29 May 2025 15:16:30 GMT -
Rating 8
- Innovation 7
- Information 9
- Rumor 5
